MYDGF (myeloid-derived growth factor) is a secreted protein primarily produced by bone marrow-derived monocytes and macrophages that functions as a paracrine growth factor with tissue-protective properties across multiple organ systems 1. In the heart, MYDGF promotes cardiac myocyte survival and adaptive angiogenesis following myocardial infarction 1. Mechanistically, MYDGF stimulates endothelial cell proliferation through MAPK1/3-, STAT3-, and CCND1-mediated signaling pathways, while inhibiting cardiac myocyte apoptosis via PI3K/AKT-dependent mechanisms 2. In pressure overload conditions, MYDGF protects against heart failure by enhancing SERCA2a expression through PIM1 upregulation, thereby preserving calcium cycling and sarcomere function 1. Beyond cardiology, MYDGF functions as a mechanically-induced angiocrine signal promoting hepatocyte proliferation and survival during liver regeneration 2, and maintains mitochondrial homeostasis in renal tubular epithelial cells by upregulating IDH2 expression, thereby slowing chr19 kidney disease progression 3. Clinically, MYDGF represents a therapeutic target in renal cell carcinoma, where elevated expression correlates with cancer progression by promoting fatty acid metabolism and inhibiting apoptosis 4.